Alumis Stock
Alumis Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Martin Babler
- Employees
- 237
- Market cap
- $792 M
- IPO
- 28/06/2024
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous…
Alumis stock: price history
1D
-3.0%
1W
-14.5%
1M
-22.9%
6M
-75.5%
YTD
-37.3%
1Y
+32.8%
2Y
-45.3%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~21% weaker price swings than usual
Ask the agents about Alumis
Analyst assessment of Alumis
PRICE TARGET LOW
US$15.00
CONSENSUS
US$29.57
MEDIAN
US$29.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 03/09/2026
Alumis stock metrics
P/E
-1.61
P/B
1.73
EV/EBITDA
-1.73
RETURN ON EQUITY
-31.5%
NET MARGIN
-8,557.2%
DEBT/EQUITY
0.08
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
70.6%
FLOAT SHARES
91,343,743
AVG. DAILY VOLUME (30D)
2,916,847
Insider transactions (SEC)
AKKARAJU SRINIVAS
AKKARAJU SRINIVAS
AKKARAJU SRINIVAS
AKKARAJU SRINIVAS
AKKARAJU SRINIVAS
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Alumis stock
What does Alumis do?
Alumis Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Martin Babler, the company employs around 237 people.
The IPO was on 28/06/2024; the stock trades on NASDAQ under the ticker ALMS.
What do analysts say about Alumis stock?
8 analysts rate the stock, the consensus is Buy (as of 03/09/2026).
The average price target is US$29.57, ranging from US$15.00 to US$40.00, with a median of US$29.00.
This is an external assessment, not a statement by Market Jury.
When does Alumis report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -21% stronger than usual.
Does Alumis pay a dividend?
No, Alumis currently does not pay a dividend.
Which stocks are comparable to Alumis?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Alumis stock analyzed?
Clicking "Analyze stock" lets five strategies assess Alumis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.